Not recruiting
Hidradenitis
Not recruitingInvestigational
Study of Tibulizumab to Treat Adults with Hidradenitis Suppurativa
Investigational
- Disease:Hidradenitis
- Substances:–
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 27
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
546 trials match your criteria
Not recruiting
Non-small cell lung cancer stage IV+1
Not recruitingInvestigationalNo placebo
Study of Zelenectide Pevedotin in Adults with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer with NECTIN4 Amplification
InvestigationalNo placebo
- Disease:Non-small cell lung cancer stage IVNon-small cell lung cancer metastatic
- Substances:ZELENECTIDE PEVEDOTIN
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:ZELENECTIDE PEVEDOTIN
Not recruiting
Small cell lung cancer
Not recruitingRegistered drugNo placebo
Study of Durvalumab for Patients with Limited Stage Small Cell Lung Cancer After Chemoradiotherapy
Registered drugNo placebo
- Disease:Small cell lung cancer
- Substances:Durvalumab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Durvalumab
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:Rocatinlimab
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Rocatinlimab
Not recruiting
Diabetic retinal oedema
Not recruitingRegistered drugNo placebo
Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema
Registered drugNo placebo
- Disease:Diabetic retinal oedema
- Substances:Eye103Fluorescein Sodium+1
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Eye103
Not recruiting
Kidney transplant rejection
Not recruitingRegistered drug
Study of Felzartamab for Patients with Late Antibody-Mediated Rejection After Kidney Transplant
Registered drug
- Disease:Kidney transplant rejection
- Substances:FelzartamabSodium Chloride
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Felzartamab
Not recruiting
Endocrine ophthalmopathy
Not recruitingRegistered drug
Study on the Safety and Effectiveness of VRDN-001 for Patients with Thyroid Eye Disease
Registered drug
- Disease:Endocrine ophthalmopathy
- Substances:Sodium ChlorideVrdn-001
Countries:Spain
Spain- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Sodium Chloride
Not recruiting
Endocrine ophthalmopathy
Not recruitingInvestigational
Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease
Investigational
- Disease:Endocrine ophthalmopathy
- Substances:VRDN-003
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:VRDN-003
Not recruiting
Chronic graft versus host disease
Not recruitingInvestigationalNo placebo
Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments
InvestigationalNo placebo
- Disease:Chronic graft versus host disease
- Substances:Axatilimab
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Axatilimab
Not recruiting
Endocrine ophthalmopathy
Not recruitingInvestigational
Study on the Effectiveness and Safety of VRDN-003 for Patients with Chronic Thyroid Eye Disease
Investigational
- Disease:Endocrine ophthalmopathy
- Substances:VRDN-003
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:VRDN-003
Not recruiting
Asthma
Not recruitingInvestigational
Study on GSK5784283 for Adults Aged 18-75 with Uncontrolled Asthma
Investigational
- Disease:Asthma
- Substances:GSK5784283
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:GSK5784283
Not recruiting
Factor VIII deficiency
Not recruitingRegistered drugNo placebo
Study on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A
Registered drugNo placebo
- Disease:Factor VIII deficiency
- Substances:Efanesoctocog Alfa
Countries:Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Efanesoctocog Alfa